Voyager Acquisition Corp/cayman Islands

Veraxa Biotech Holding AG has entered into a securities purchase agreement for a $27.5 million senior secured note and a $50 million share purchase agreement with Lincoln Park Capital Fund, bolstering its financial position.

Voyager Acquisition Corp. shareholders approved the business combination with Veraxa Biotech AG, despite a high redemption rate of 99.67% of Class A shares.

VERAXA Biotech AG shareholders have approved the merger with Voyager Acquisition Corp. and the issuance of new shares, moving closer to a NASDAQ listing under the symbol VRXA.

Voyager Acquisition Corp. amended its business combination agreement with Veraxa Biotech AG, increasing the merger consideration to $1.35 billion and adjusting sponsor equity.

Voyager Acquisition Corp. and Veraxa Biotech AG have amended their business combination agreement, extending the merger deadline to August 7, 2026, and modifying termination fee provisions.

Voyager Acquisition Corp. announced a definitive business combination agreement with Veraxa Biotech AG, a Swiss oncology company, valuing the combined entity at approximately $1.3 billion.

Voyager Acquisition Corp. reports Q1 2026 financial results while progressing toward its business combination with Veraxa Biotech AG.

Voyager Acquisition Corp. reported increased net income for Q3 2025 and the nine months ended September 30, 2025, while progressing its business combination with Veraxa Biotech AG.

Voyager Acquisition Corp. reported a net income of $2.49 million for Q2 2025, driven by trust account interest, and announced a definitive business combination agreement with Veraxa Biotech AG.

Voyager Acquisition Corp. reports net income for Q1 2025 and announces a business combination agreement with Veraxa Biotech AG.

Voyager Acquisition Corp. reported a net income of $1.2 million for the nine months ended September 30, 2024, primarily driven by interest and unrealized gains from investments held in trust after its initial public offering.

Voyager Acquisition Corp. reports a net loss of $102,848 for the six months ended June 30, 2024, while also completing its initial public offering in August.

Voyager Acquisition Corp. filed an amendment to its 2025 Annual Report to include a previously omitted executive compensation recoupment policy.

Voyager Acquisition Corp.'s 10-K filing outlines the company's share structure, warrant details, and governance policies as of December 31, 2024.

VERAXA Biotech AG shareholders have approved the merger with Veraxa Biotech Holding AG and the issuance of new shares to Voyager Acquisition Corp., moving closer to a NASDAQ listing.

Voyager Acquisition Corp. and Veraxa Biotech AG amended their business combination agreement, increasing the merger consideration to $1.35 billion and adjusting sponsor share forfeitures.

Voyager Acquisition Corp. and Veraxa Biotech AG amended their Business Combination Agreement, extending the merger completion deadline to August 7, 2026, and modifying termination fee provisions.

VERAXA Biotech and Secarna Pharmaceuticals announce a strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for autoimmune and inflammatory diseases.

Voyager Acquisition Corp. announces a definitive business combination agreement with Veraxa Biotech AG, valuing the combined entity at approximately $1.5 billion.

VERAXA Biotech and Voyager Acquisition Corp. announced the filing of a Form F-4 Registration Statement with the SEC, marking a key step towards their proposed business combination and VERAXA's public listing.

Voyager Acquisition Corp. updates its S-1 filing, detailing warrant agreements and initial public offering plans.

Voyager Acquisition Corp., a blank check company, has filed an amendment to its Form S-1 registration statement for a proposed $261 million initial public offering.

Voyager Acquisition Corp., a blank check company, aims to raise $261 million in an IPO to pursue a business combination within the healthcare or related industries.

Magnetar entities and David J. Snyderman confirm joint filing agreement for Voyager Acquisition Corp. shares as of March 31, 2026.

First Trust Merger Arbitrage Fund and affiliates report a combined beneficial ownership of 2.47% in Voyager Acquisition Corp.

Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed an amended Schedule 13G, reporting beneficial ownership of 2.7% of Voyager Acquisition Corp's Class A ordinary shares as of March 31, 2026.

W. R. Berkley Corporation and its subsidiary, Berkley Insurance Company, have reported a 5.2% beneficial ownership stake in Voyager Acquisition Corp.

Wolverine Asset Management and associated parties have reported a 0% beneficial ownership stake in Voyager Acquisition Corp.

LMR Partners and its affiliates have reported a passive 4.1% beneficial ownership stake in Voyager Acquisition Corp.'s Class A Ordinary Shares as of December 31, 2025.